| Also known as |
TH9507 |
| Blood pressure |
Typically no significant impact on blood pressure |
| Chemical name |
(trans-3-Hexenoyl)lysyl-threonyl-threonyl-threonyl-lysyl-threonyl-lysyl-threonyl-lysyl-threonyl-lysyl-threonyl-lysyl-threonyl |
| Dosage (medical) |
2 mg injected subcutaneously once daily |
| Dosage (sports) |
Not applicable as it is not typically used for sports enhancement |
| Effects |
Increases natural production of growth hormone |
| Formula |
C221H366N72O67S |
| Half-life |
Approximately 38 minutes |
| Hepatotoxicity |
No significant hepatotoxicity reported |
| Lab Test |
Monitoring of IGF-1 levels may be used to assess efficacy |
| Main action |
Growth hormone-releasing hormone (GHRH) analog |
| Raw Material |
Human Growth Hormone |
| Side effects |
Injection site reactions (redness, itching, pain), muscle aches, swelling, and potential increase in blood sugar levels |
| Storage conditions |
Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F) |
| Substance class |
Peptide hormone |
| Trade name |
Egrifta |
| Use in sports |
Not commonly used due to its specific medical application for reducing excess abdominal fat in HIV-infected patients with lipodystrophy |
| Water Retention |
Minimal |
| Manufacturer |
Generic blue top |
| Packing |
Tesamorelin 2mg |
